Effective January 1, 2004, the Singapore Health Sciences Authority (HSA) launched a consolidated Center for Drug Administration (CDA). The center was formed as a result of a merger between two of HSA’s former professional centers responsible for the regulation and evaluation of medicinal products – the Center for Pharmaceutical Administration (CPA) and the Center for Drug Evaluation (CDE).
The CDA’s mission is to further rationalize and streamline the systems and processes for the evaluation and registration of western medicinal products in Singapore. Such procedures used to be completed by various arms of the CPA and CDE, but synergizing processes and systems is in line with HSA’s objective of providing seamless regulatory services.
The merger will not affect external operational interfaces for points of contact for product applications. The former CDE department responsible for that is now called the Innovative Therapeutics Group, and is part of the new CDA’s Product Evaluation and Registration Division.